在低风险差异化甲状腺癌中评估levothyroxine治疗的充分性:一个多中心队列研究
Juan J Díez1,2,3, Emma Anda4, Victoria Alcazar2,5
1Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain.
Frontiers in endocrinology
|December 29, 2025
概括
在差异化甲状腺癌 (DTC) 患者中,levothyroxine治疗的充分性仍然很低,许多患者接受的剂量不足或过多. 在低风险的DTC管理中,个性化剂量对于优化结果和最大限度地降低风险至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 差异化甲状腺癌 (DTC) 的管理通常涉及levothyroxine治疗.
- 评估这种治疗的充分性,特别是在低风险的DTC患者中,对于长期结果至关重要.
- 血清甲状腺激素 (TSH) 水平是评估levothyroxine治疗有效性的关键指标.
研究的目的:
- 评估Levothyroxine治疗在患有低风险差异化甲状腺癌 (DTC) 的患者中的充分性.
- 评估TSH水平并确定遵守美国甲状腺协会 (ATA) 关于Levothyroxine剂量的指南.
- 确定导致DTC患者莱沃西素剂量不足的因素.
主要方法:
- 进行了一项多中心的回顾性队列研究.
- 包括患有低风险DTC的患者,根据2015年ATA指南按风险分层.
- 以TSH水平相对于ATA推的目标来确定levothyroxine的充分性.
主要成果:
- 分析了1016名患有低风险DTC的患者 (平均随访时间为6.6年).
- 治疗充分性从12个月后的26.0%增加到最终随访时的39.5% (P<0.001).
- 不足是由于30.5%的优异反应患者过度服用莱沃西,而62.2%的不确定/生化不完整反应患者的剂量不足.
结论:
- 治疗充足率较低表明需要个性化的勒沃西剂量策略.
- 优化levothyroxine剂量对于改善低风险DTC的治疗结果至关重要.
- 尽量减少与低剂量或过量剂量相关的风险,对于患者的健康至关重要.
相关概念视频
Synthesis and Regulation of Thyroid Hormones
7.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.0K
The Thyroid Gland
6.5K
The thyroid gland is a small, butterfly-shaped gland located in the neck and covers the anterior surface of the trachea. The gland has two lateral lobes connected by a thin tissue mass called the isthmus. Internally, each lobe comprises many small spherical structures known as thyroid follicles, surrounded by a network of blood vessels.
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
6.5K
Therapeutic Drug Monitoring: Overview and Classification
264
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
264
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Bioequivalence of Drugs: Drugs with Multiple Indications
138
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
138


